16 September 2024
The Smorodintsev Research Institute of Influenza, a federal institution under the Russian Ministry of Health, is in the process of creating a long-lasting vaccine against the influenza A virus. This innovative vaccine aims to provide protection against infection for several years. The director of the research institute, Dmitry Lioznov, announced at a conference in Novosibirsk that the drug is now in the preclinical trial phase.
He explains that the development is still in its early stages and has not yet entered clinical trials. The vaccine is designed to be administered just once every few years, offering long-lasting protection. The drug is being developed taking into account the current circulating strains of the virus.
Print06 September 2024
NovaMedica expands its line of products for the treatment of Alzheimer’s disease
22 August 2024
Children visited the NovaMedica Innotech pharmaceutical manufacturing facility
14 June 2024
87% of cancer patients give positive ratings for medical care quality
18 September 2024
The Russian market of fillers and biorevitalizers grew by 21% in the first half of 2024
18 September 2024
Pharma’s Patient Reach Problem: Billions Still Left Behind
17 September 2024
17 September 2024